PAM
HTGM

Panagora Asset Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Panagora Asset Management’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-400
Closed -$122K – 2379
2017
Q3 		$122K Buy
+400
New +$152K ﹤0.01% 1842
2015
Q4 		– Sell
-135
Closed -$185K – 2396
2015
Q3 		$185K Buy
135
+32
+31% +$49.4K ﹤0.01% 1625
2015
Q2 		$206K Buy
+103
New +$263K ﹤0.01% 1666

Other funds holding HTGM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
PWP
Private Wealth Partners Mill Valley, California $1.3B AUM 26.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Panagora Asset Management's HTGM Position: Q4 2017 in Review

Panagora Asset Management sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2017, closing a stake of 400 shares — an estimated $122K sold.

Panagora Asset Management first reported a position in HTGM in Q2 2015 and held it in 3 quarters. The position peaked at $206K in Q2 2015. 17 funds tracked by Wall St. Rank hold HTGM as of Q4 2017.

  • Panagora Asset Management reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Panagora Asset Management sold 400 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2017, an estimated $122K.
  • Panagora Asset Management first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2015 and held it in 3 quarters.
  • Panagora Asset Management's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $206K in Q2 2015.
  • 17 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2017.

Based on Panagora Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.